The U.S. Food and Drug Administration has a approved a companion diagnostic test for treatment of non-small cell lung cancer developed by Roche Tissue Diagnostics, known locally as Ventana Medical Systems.

The Ventana ALK (D5F3) CDx Assay can be used to identify patients that are positive for a key protein that makes them eligible for treatment with the Roche drug Alecensa.

The new test, the only FDA-approved companion diagnostic for the medication, is available for use on the Roche BenchMark XT or BenchMark ULTRA IHC/ISH slide staining systems.

Ventana now has six FDA-approved companion or complementary diagnostics for use in four cancers — non-small cell lung cancer, metastatic urothelial cancer, breast cancer and gastrointestinal stromal tumors.